Moreover, Kuo et al. showed that treatment with Eritoran in murine models of colorectal carcinoma was able to inhibit the progression of bacterial LPS-induced colon cancer through induction of CD14/Src/PKCζ-mediated apoptosis and the blockade of TLR4-dependent proliferation [149]. The gene discussed is TLR4; the disease is malignant colon neoplasm.